Vanguard Capital Management’s Abeona Therapeutics ABEO Stock Holding History
Bought
Maintained
Sold
Other funds holding ABEO
ACM
AIC
Vanguard Capital Management's ABEO Position: Q3 2026 in Review
Vanguard Capital Management reduced its Abeona Therapeutics (ABEO) stake by 3.3% in Q3 2026, selling an estimated $457K and leaving 2,137,768 shares worth $11.2M. The position accounts for ﹤0.01% of the portfolio, ranked #2689.
Vanguard Capital Management first reported a position in ABEO in Q1 2026 and has held it in 3 quarters since. The position peaked at $13.7M in Q2 2026. 115 funds tracked by Wall St. Rank hold ABEO as of Q3 2026.
- Vanguard Capital Management held 2,137,768 shares of Abeona Therapeutics worth $11.2M as of Q3 2026.
- Vanguard Capital Management sold 73,665 Abeona Therapeutics shares in Q3 2026, an estimated $457K.
- Abeona Therapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q3 2026, its #2689 holding.
- Vanguard Capital Management first reported a position in Abeona Therapeutics in Q1 2026 and has held it in 3 quarters since.
- Vanguard Capital Management's Abeona Therapeutics position peaked at $13.7M in Q2 2026.
- 115 funds tracked by Wall St. Rank held Abeona Therapeutics as of Q3 2026.
Based on Vanguard Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.